ClavystBio

ClavystBio is a life sciences investor and venture builder established by Temasek to accelerate the commercialization of biotech, medtech, and digital health breakthroughs from ideation to health impact. The company invests and partners with innovators, entrepreneurs, and founders to launch and grow global companies from Singapore. ClavystBio's mission is to catalyze global health solutions by leveraging Singapore's strengths in the life sciences sector.

The firm's investment strategy focuses on early-stage ventures, including pre-seed, seed, and Series A rounds, with investments ranging from a couple of million to $20 million. ClavystBio's portfolio spans therapeutics, digital health, and medtech sectors, emphasizing first-in-class science and technology. The company also fosters partnerships among academia, industry, and investors, and convenes life sciences communities at its collaborative innovation space, Node 1, to advance Singapore as a global life sciences translational hub.

Since its inception in 2022, ClavystBio has committed over US$220 million to biotech, diagnostics, and digital health companies, as well as early-stage VC funds. The firm's track record includes investments in companies like Respiree, which closed a US$11.6 million Series A financing round led by ClavystBio in July 2025. This investment underscores ClavystBio's commitment to supporting innovative health tech solutions that enhance patient care and empower clinical teams with actionable insights.

ClavystBio's collaborative approach and strategic investments aim to bridge the gap in Singapore's biotech ecosystem, providing the necessary capital and expertise to scale innovative health solutions globally. By partnering with various stakeholders, ClavystBio seeks to create a vibrant and supportive community that drives the growth of the life sciences sector in Singapore and beyond.